Neuren Pharmaceuticals Limited ( (AU:NEU) ) has provided an update.
Neuren Pharmaceuticals reported significant growth in the sales of DAYBUE™ (trofinetide) in 2024, with net sales reaching US$348.4 million in the United States, marking a 97% increase from 2023. Acadia Pharmaceuticals, Neuren’s partner, is implementing strategies to further boost adoption among Rett syndrome patients, with plans to expand sales in Canada and Europe. Neuren anticipates substantial royalties from these sales, projecting between A$62 million and A$67 million for 2025. This growth positions Neuren strongly in the neurological disorder treatment market, highlighting the potential for further expansion and increased shareholder value.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited is focused on developing new drug therapies for serious neurological disorders that arise in early childhood, which currently have no or limited approved treatment options. The company has been granted ‘orphan drug’ designation in the United States for its programs, providing incentives for developing treatments for rare and serious diseases. Neuren’s lead product, DAYBUE™ (trofinetide), is approved for treating Rett syndrome, and the company has licensed its development and commercialization to Acadia Pharmaceuticals. Neuren is also developing NNZ-2591 for other neurodevelopmental disorders.
YTD Price Performance: 12.63%
Average Trading Volume: 612
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.1B
Learn more about NEU stock on TipRanks’ Stock Analysis page.